Changes in Skeletal Muscle Qualities During Enzyme Replacement Therapy in Late-onset Type II Glycogenosis: Temporal and Spatial Pattern of Mass Vs. Strength Response

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2010 Sep 17

PMID 20844963

Citations 15

Authors

Sabrina Ravaglia

Anna Pichiecchio

Michela Ponzio

Cesare Danesino

Kolsoum Saeidi Garaghani

Guy Umberto Poloni

Antonio Toscano

Arrigo Moglia

Annalisa Carlucci

Paola Bini

Mauro Ceroni

Stefano Bastianello

Affiliations

Soon will be listed here.

Abstract

Muscle quality is defined as muscle strength generated per unit muscle mass. If enzyme replacement therapy (ERT) has some effects on type II glycogenosis (GSDII) skeletal muscle pathology, we should be able to measure a change in strength and mass. We conducted a prospective study including 11 patients aged 54.2 ± 11.2 years, referring to a single institution and receiving ERT for ≥2 years. Median Walton score was 3 (2.5-6). Lower limb skeletal muscles were assessed by dynamometry and quantitative muscle MRI. Three segments (anterior thigh, posterior thigh, leg) were analysed separately. Clinical-MRI correlations were searched for at T0, T6/T8, and T18/24. Changes in lean and fat body composition were assessed by bioelectrical impedance analysis. We found that the anterior thigh showed the best therapeutic response, with an improvement in muscle quality (muscle mass: +7.5%, p = 0.035; strength: +45%, p = 0.002). BMI and lean body mass increased (p = 0.007). Patients with low BMI showed a better outcome. Intramuscular fat accumulation significantly progressed in spite of ERT (+3.7%, p = 0.001), especially in the poorly responsive posterior thigh muscles. Both clinical assessment and MRI revealed a definite improvement in the anterior thigh muscles. However, progression of intramuscular fat accumulation during ERT, as well as the limited responsiveness of posterior thigh muscles, suggests the necessity for early treatment intervention. The better outcome of patients with low BMI, if confirmed, may indicate that dietary protocols could be adopted as adjuvant measures to ERT in adult GSDII.

Citing Articles

Bioimpedance Phase Angle as a Prognostic Tool in Late-Onset Pompe Disease: A Single-Centre Prospective Study With a 15-year Follow-Up.

Ravaglia S, De Giuseppe R, Carlucci A, Jehne S, Crescimanno G, Ahmad L Front Cell Dev Biol. 2022; 10:793566.

PMID: 35252175 PMC: 8896115. DOI: 10.3389/fcell.2022.793566.

Six-Minute Walk Distance Is a Useful Outcome Measure to Detect Motor Decline in Treated Late-Onset Pompe Disease Patients.

Claeys K, DHondt A, Fache L, Peers K, Depuydt C Cells. 2022; 11(3).

PMID: 35159144 PMC: 8834389. DOI: 10.3390/cells11030334.

A Systematic Review and Meta-Analysis of Enzyme Replacement Therapy in Late-Onset Pompe Disease.

Dornelles A, Junges A, Pereira T, Krug B, Goncalves C, Llerena Jr J J Clin Med. 2021; 10(21).

PMID: 34768348 PMC: 8584814. DOI: 10.3390/jcm10214828.

Quantitative Muscle MRI in Patients with Neuromuscular Diseases-Association of Muscle Proton Density Fat Fraction with Semi-Quantitative Grading of Fatty Infiltration and Muscle Strength at the Thigh Region.

Schlaeger S, Sollmann N, Zoffl A, Becherucci E, Weidlich D, Kottmaier E Diagnostics (Basel). 2021; 11(6).

PMID: 34201303 PMC: 8230029. DOI: 10.3390/diagnostics11061056.

Regional variation of thigh muscle fat infiltration in patients with neuromuscular diseases compared to healthy controls.

Greve T, Burian E, Zoffl A, Feuerriegel G, Schlaeger S, Dieckmeyer M Quant Imaging Med Surg. 2021; 11(6):2610-2621.

PMID: 34079727 PMC: 8107331. DOI: 10.21037/qims-20-1098.

References

Ravaglia S, Danesino C, Pichiecchio A, Repetto A, Poloni G, Rossi M . Enzyme replacement therapy in severe adult-onset glycogen storage disease type II. Adv Ther. 2008; 25(8):820-9. DOI: 10.1007/s12325-008-0086-y. View

Luden N, Minchev K, Hayes E, Louis E, Trappe T, Trappe S . Human vastus lateralis and soleus muscles display divergent cellular contractile properties. Am J Physiol Regul Integr Comp Physiol. 2008; 295(5):R1593-8. PMC: 2584861. DOI: 10.1152/ajpregu.90564.2008. View

Kishnani P, Hwu W, Mandel H, Nicolino M, Yong F, Corzo D . A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006; 148(5):671-676. DOI: 10.1016/j.jpeds.2005.11.033. View

Ravaglia S, Danesino C, Moglia A, Costa A, Cena H, Maccarini L . Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis. Eur J Neurol. 2010; 17(7):957-62. DOI: 10.1111/j.1468-1331.2010.02959.x. View

van der Ploeg A, Clemens P, Corzo D, Escolar D, Florence J, Groeneveld G . A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med. 2010; 362(15):1396-406. DOI: 10.1056/NEJMoa0909859. View

Slonim A, Bulone L, Goldberg T, Minikes J, Slonim E, Galanko J . Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve. 2006; 35(1):70-7. DOI: 10.1002/mus.20665. View

Lynch N, Metter E, Lindle R, Fozard J, Tobin J, Roy T . Muscle quality. I. Age-associated differences between arm and leg muscle groups. J Appl Physiol (1985). 1999; 86(1):188-94. DOI: 10.1152/jappl.1999.86.1.188. View

Enright P, Sherrill D . Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998; 158(5 Pt 1):1384-7. DOI: 10.1164/ajrccm.158.5.9710086. View

Gerrits K, Beltman M, Koppe P, Konijnenbelt H, Elich P, de Haan A . Isometric muscle function of knee extensors and the relation with functional performance in patients with stroke. Arch Phys Med Rehabil. 2009; 90(3):480-7. DOI: 10.1016/j.apmr.2008.09.562. View

10.

Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C . Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol. 2009; 257(1):91-7. DOI: 10.1007/s00415-009-5275-3. View

11.

Hagemans M, Winkel L, van Doorn P, Hop W, Loonen M, Reuser A . Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain. 2005; 128(Pt 3):671-7. DOI: 10.1093/brain/awh384. View

12.

Bohannon R . Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years. Arch Phys Med Rehabil. 1997; 78(1):26-32. DOI: 10.1016/s0003-9993(97)90005-8. View

13.

Laaban J, Kouchakji B, Dore M, Orvoen-Frija E, David P, ROCHEMAURE J . Nutritional status of patients with chronic obstructive pulmonary disease and acute respiratory failure. Chest. 1993; 103(5):1362-8. DOI: 10.1378/chest.103.5.1362. View

14.

Ravaglia S, Moglia A, Costa A, Repetto A, Danesino C . Enzyme replacement therapy in late-onset type II glycogenosis. Eur J Neurol. 2009; 16(7):e125. DOI: 10.1111/j.1468-1331.2009.02667.x. View

15.

Pichiecchio A, Poloni G, Ravaglia S, Ponzio M, Germani G, Maranzana D . Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful?. Muscle Nerve. 2009; 40(1):122-5. DOI: 10.1002/mus.21304. View

16.

Jankowska E, Wegrzynowska K, Superlak M, Nowakowska K, Lazorczyk M, Biel B . The 12-week progressive quadriceps resistance training improves muscle strength, exercise capacity and quality of life in patients with stable chronic heart failure. Int J Cardiol. 2007; 130(1):36-43. DOI: 10.1016/j.ijcard.2007.07.158. View

17.

Fukuda T, Ahearn M, Roberts A, Mattaliano R, Zaal K, Ralston E . Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther. 2006; 14(6):831-9. PMC: 2693339. DOI: 10.1016/j.ymthe.2006.08.009. View

18.

van der Ploeg R, Fidler V, OOSTERHUIS H . Hand-held myometry: reference values. J Neurol Neurosurg Psychiatry. 1991; 54(3):244-7. PMC: 1014394. DOI: 10.1136/jnnp.54.3.244. View

19.

Kobayashi H, Shimada Y, Ikegami M, Kawai T, Sakurai K, Urashima T . Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case. Mol Genet Metab. 2010; 100(1):14-9. DOI: 10.1016/j.ymgme.2010.01.015. View

20.

van den Hout J, Kamphoven J, Winkel L, Arts W, de Klerk J, Loonen M . Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004; 113(5):e448-57. DOI: 10.1542/peds.113.5.e448. View